MADRID, Oct. 26 (EUROPA PRESS) –
The coordinator of Pathological Anatomy of the Breast Area of the Ribera Health Group, Dr. Laia Bernet, said that “investing in diagnosis means saving in pharmacies and earning health for patients” with breast cancer.
This was one of the main conclusions of the symposium organized by Agendia and Health in Code at the Congress of the Spanish Society of Senology and Breast Pathology (SESPM), held in Oviedo from 18 to 21 October.
This symposium, framed in an event that brought together leading professionals in the field and in the context of Breast Cancer Awareness Month, sought to answer the question of whether doctors can do without the genetic signature to make decisions and why to choose the ‘MammaPrint + BluePrint Test’. In the,
Also attended by Dr. Jon Mieza, gynecologist of the Deusto Gynecological Institute, who presented his experience of over 10 years of working with this platform to optimize the treatment of patients.
‘MammaPrint + BluePrint’ is a genomic test that analyzes 150 genes and provides prognostic information about the tumor and predictive information on the efficacy of potential treatments by studying the expression in each tumor of a range of genes and proteins derived from those genes.
“We cannot continue to do as 20 years ago. Before tools such as genomics and transcriptomics seemed like science fiction, but now we have to ask ourselves if the classic and known techniques such as immunohistochemistry and others are sufficient to offer the best treatment to patients or can we add more resources “, assured Laia Bernet.
“Today, technology supports us and ensures that modern transcriptomics and genomics techniques are part of the regulations of our services and we have them at our fingertips to improve diagnosis,” he said.
On the one hand, the ‘MammaPrint’ test allows to establish the risk of relapse and to determine whether chemotherapy and hormone therapy would be useful or could be avoided to improve the quality of life of patients. On the other hand, the complementary test ‘BluePrint’ provides added value and allows you to have more precise information on the type of tumor and to classify it according to its degree of aggressiveness.
